...
首页> 外文期刊>Human gene therapy. Clinical development >LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma
【24h】

LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma

机译:LNCRNA HOXA-AS3海绵MIR-29C,以促进细胞增殖,转移和EMT过程,并在肝细胞癌中激活MEK / ERK信号通路

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is a prevalent malignant tumor with high morbidity and mortality across the world. Recent findings have suggested that long noncoding (lnc)RNA HOXA-AS3 plays an important role in tumorigenesis and metastasis in a variety of cancers. However, the role of lncRNA HOXA-AS3 in the initiation and progression of HCC remains largely unclear. In the present study, HOXA-AS3 was highly expressed in HCC tumor tissues and cell lines. High HOXA-AS3 expression was correlated with low survival of HCC patients. Loss-of-function experiments showed that knockdown of HOXA-AS3 inhibited cell proliferation, migration, invasion, the epithelial-mesenchymal transition (EMT) process, and the mitogen-activated protein kinase/extracellular regulated protein kinase (MEK/ERK) signaling pathway in HCC. Molecular mechanism exploration uncovered that HOXA-AS3 could directly interact with and negatively regulate miR-29c. BMP1 is a downstream target gene of miR-29c, and HOXA-AS3 could regulate BMP1 expression by targeting miR-29c. miR-29c negatively regulated and BMP1 promoted the progression of HCC. Rescue experiments revealed that miR-29c inhibitor could partially counteract the impact induced by HOXA-AS3 knockdown in HCC. Taken together, our study is the first to show the interaction of HOXA-AS3 with miR-29c in facilitating cell proliferation, metastasis, EMT process, and MEK/ERK signaling pathway in HCC.
机译:肝细胞癌(HCC)是一种普遍存在的恶性肿瘤,全世界的发病率高,死亡率高。最近的发现表明,长度非编码(LNC)RNA Hoxa-As3在各种癌症中发挥着重要作用和转移。然而,LNCRNA HOXA-AS3在HCC的开始和进展中的作用仍然不清楚。在本研究中,HOXA-AS3在HCC肿瘤组织和细胞系中高度表达。 HIGHOXA-AS3表达与HCC患者的低存活率相关。函数丧失实验表明,Hoxa-AS3的敲低抑制细胞增殖,迁移,侵袭,上皮间过渡转变(EMT)方法和丝裂原激活蛋白激酶/细胞外调节蛋白激酶(MEK / ERK)信号通路在HCC中。分子机制探测发现,Hoxa-AS3可以直接与miR-29c直接相互作用。 BMP1是miR-29c的下游靶基因,HOXA-AS3可以通过靶向miR-29c来调节BMP1表达。 MiR-29C负调节,BMP1促进了HCC的进展。救援实验表明,miR-29c抑制剂可以部分地抵消HCC敲低的HOXA-AS3敲低的影响。我们的研究成功,是第一个显示HOXA-AS3与MIR-29C的相互作用促进HCC中的细胞增殖,转移,EMT过程和MEK / ERK信号通路。

著录项

  • 来源
  • 作者单位

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

    Zhejiang Prov Peoples Hosp Dept Infect Dis Hangzhou 310014 Zhejiang Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医学遗传学;
  • 关键词

    HOXA-AS3; miR-29c; BMP1; HCC;

    机译:HOXA-AS3;MIR-29C;BMP1;HCC;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号